|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV:a phase 2 trial显示文摘The increased coronavirus disease 2019(COVID-19)breakthrough cases pose the need of booster vaccination.We conducted a randomised,double-blinded,controlled,phase 2 trial to assess the immunogenicity and safety of the heterologous prime-boost vaccination with an inactivated COVID-19 vaccine(BBIBP-CorV)followed by a recombinant protein-based vaccine(NVSI-06-07),using homologous boost with BBIBP-CorV as control.Three groups of healthy adults(600 individuals per group)who had completed two-dose BBIBP-CorV vaccinations 1–3 months,4–6 months and≥6 months earlier,respectively,were randomly assigned in a 1:1 ratio to receive either NVSI-06-07 or BBIBP-CorV boost.Immunogenicity assays showed that in NVSI-06-07 groups,neutralizing antibody geometric mean titers(GMTs)against the prototype SARS-CoV-2 increased by 21.01–63.85 folds on day 28 after vaccination,whereas only 4.20–16.78 folds of increases were observed in control groups.For Omicron variant,the neutralizing antibody GMT elicited by homologous boost was 37.91 on day 14,however,a significantly higher neutralizing GMT of 292.53 was induced by heterologous booster.Similar results were obtained for other SARS-CoV-2 variants of concerns(VOCs),including Alpha,Beta and Delta.Both heterologous and homologous boosters have a good safety profile.Local and systemic adverse reactions were absent,mild or moderate in most participants,and the overall safety was quite similar between two booster schemes.Our findings indicated that NVSI-06-07 is safe and immunogenic as a heterologous booster in BBIBP-CorV recipients and was immunogenically superior to the homologous booster against not only SARS-CoV-2 prototype strain but also VOCs,including Omicron. | Nawal Al Kaabi Yun Kai Yang Jing Zhang Ke Xu Yu Liang Yun Kang Ji Guo Su Tian Yang Salah Hussein Mohamed Saif ElDein Shuai Shao Sen Sen Yang Wenwen Lei Xue Jun Gao Zhiwei Jiang Hui Wang Meng Li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue Zhang Chang Qu Dan Ying Liu Jing Zhang Mengjie Yang Islam Eltantawy Peng Xiao Zhao Nian Wang Jin Liang Yin Xiao Yan Mao Jin Zhang Ning Liu Fu Jie Shen Liang Qu Yun Tao Zhang Xiao Ming Yang Guizhen Wu Qi Ming Li | 2022 | Signal Transduction and Targeted Therapy2022，7，7： | 2 |
| 2 | Device-associated infection rates in adult and pediatric intensive care units of hospitals in Egypt. International Nosocomial Infection Control Consortium (INICC) findings显示文摘 | Ossama Rasslan Zeinab Salah Seliem Islam Abdullorziz Ghazi Muhamed Abd El Sabour Amani Ali El Kholy Fatma Mohamed Sadeq Mahmoud Kalil Doaa Abdel-Aziz Hosnia Yousif Sharaf Adel Saeed Hala Agha Sally Abd El-Wadood Zein El-Abdeen Maha El Gafarey Amira El Tan | 2012 | Journal of Infection and Public Health2012，，6： | 1 |
| 3 | Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party显示文摘 | Judith C. Marsh Andrea Bacigalupo Hubert Schrezenmeier Andre Tichelli Antonio M. Risitano Jakob R. Passweg Sally B. Killick Alan J. Warren Theodora Foukaneli Mahmoud Aljurf H. A. Al-Zahrani Philip Schafhausen Alexander Roth Anke Franzke Tim H. Brummendorf | 2012 | Blood2012，，23： | 1 |
| 4 | Diffusion-weighted MR imaging and ADC measurement in normal prostate, benign prostatic hyperplasia and prostate carcinoma显示文摘 | Sally Emad-Eldin Manal Halim Lamiaa I.A. Metwally Rania Mahmoud Abdel-Aziz | 2014 | The Egyptian Journal of Radiology and Nuclear Medicine2014，，： | 1 |
| 5 | Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants:a randomized phase 2 trial显示文摘An ongoing randomized,double-blind,controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate,named NVSI-06-09,as a booster dose in subjects aged 18 years and older from the United Arab Emirates(UAE),who had administered two or three doses of inactivated vaccine BBIBP-CorV at least 6 months prior to enrollment.The participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or BBIBP-CorV.The primary outcomes were immunogenicity and safety against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron variant,and the exploratory outcome was cross-immunogenicity against other circulating strains.Between May 25 and 30,2022,516 adults received booster vaccination with 260 in NVSI-06-09 group and 256 in BBIBP-CorV group.Interim results showed a similar safety profile between two booster groups,with low incidence of adverse reactions of grade 1 or 2.For immunogenicity,by day 14 post-booster,the fold rises in neutralizing antibody geometric mean titers(GMTs)from baseline elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain(19.67 vs 4.47-fold),Omicron BA.1.1(42.35 vs 3.78-fold),BA.2(25.09 vs 2.91-fold),BA.4(22.42 vs 2.69-fold),and BA.5 variants(27.06 vs 4.73-fold).Similarly,the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those by BBIBP-CorV.Our findings indicated that a booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against divergent SARS-CoV-2 variants,including Omicron and its sub-lineages. | Nawal Al Kaabi Yun Kai Yang Yu Liang Ke Xu Xue Feng Zhang Yun Kang Yu Qin Jin Jun Wei Hou Jing Zhang Tian Yang Salah Hussein Mohamed Saif ElDein Ze Hua Lei Hao Zhang Shuai Shao Zhao Ming Liu Ning Liu Xiang Zheng Ji Guo Su Sen Sen Yang Xiangfeng Cong Yao Tan Wenwen Lei Xue Jun Gao Zhiwei Jiang Hui Wang Meng Li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue Zhang Chang Qu Dan Ying Liu Jing Zhang Mengjie Yang Islam Eltantawy Peng Xiao Fu Jie Shen Jin Juan Wu Zi Bo Han Li Fang Du Fang Tang Shi Chen Zhi Jing Ma Fan Zheng Ya Nan Hou Xin Yu Li Xin Li Zhao Nian Wang Jin Liang Yin Xiao Yan Mao Jin Zhang Liang Qu Yun Tao Zhang Xiao Ming Yang Guizhen Wu Qi Ming Li | 2023 | Signal Transduction and Targeted Therapy2023，8，2： | 0 |
| 6 | Antimicrobial activities of three seaweeds extract against some human viral and bacterial pathogens显示文摘Microbial infections cause complicated health influences along with bad economic impacts.In the present investigation,three dominant seaweeds namely,Amphiroa anceps,Corallina officinalis and Sargassum filipendula were collected from different Egyptian sites at the Red Sea and Mediterranean Sea during autumn 2019.Organic extracts of the three algae were screened for their antibacterial activity against three pathogenic bacteria Salmonella typhiimurium,Staphylococcus aureus and Escherichia coli,in addition to in vitro antiviral activity against Rotavirus(RV),and Coxsackie virus B3(CVB3)that cause severe diseases in human.Organic extract of A.anceps,C.officinalis and S.filipendula inhibit E.coli cells by 57.1%,85.7%,and 91.4%,respectively.The highest level of concentration of the C.officinalis extract(100μg/mL)inhibits 100%of Staphylococcus aureus cells followed by S.filipendula and A.anceps extract which inhibit 82.5%and 75%of S.aureus.Similarly,the highest concentration of C.officinalis extract inhibits S.typhiimurium by 80%.The extract of A.anceps exhibited a high antiviral effect against RV infection with TI=22 and virus titers lessened by 2.75 log TCID_(50) followed by extractions of C.officinalis with TI=18.3 and virus titers reduced by 2.5 log TCID_(50).Against CVB3 infection,the extract of A.anceps causes the highest antiviral activity with TI=15 and reduce the viral titers by 2.5 log TCID_(50),followed by extractions of C.officinalis with TI=8.8 and inhibition of virus titers by 1.75 log TCID_(50).Extract of S.filipendula displayed the lowest antiviral effects against RV and CVB3 infection with TI=2.4 and 1.4,respectively.The obtained results clarified that the extract of three marine seaweeds maintains a potent antimicrobial activity,making them a future promising source of new antimicrobial drugs. | JELAN MOFEED MOHAMED DEYAB ABDELNASER MOHAMED MAHMOUD MOUSTAFA SALLY NEGM EMAD EL-BILAWY | 2022 | BIOCELL2022，46，1： | 0 |
| 7 | Secondary antiviral metabolites from fungi with special reference to coronaviruses显示文摘Profound inspection of the life forms on the earth teaches how to be the complexity of interrelationships among the various systems.Because of the emergence of novel viruses all the time and the inadequate of vaccines and antivirals,viral contagions are amongst the most causative diseases affecting people worldwide.Fungi exemplify a massive source of bioactive molecules as,many fungal secondary metabolities like Oxoglyantrypine,Carneic acid F,Scedapin C,Asteltoxin E,Phomanolide,Norquinadoline A and Quinadoline B have antiviral activity.This review deals with how secondary metabolites of fungi can help in the war against viruses in general and especially Coronaviruses moreover several pieces of literature pointed out that many clusters of fungi in different biotopes are waiting to be exploited. | MOHAMED SALEM MOHAMMAD EL-METWALLY WESAMELDIN SABER SALLY NEGM ATTALLA EL-KOTT YASSER MAZROUA ABEER MAKHLOUF MAHMOUD MOUSTAFA | 2022 | BIOCELL2022，46，8： | 0 |
| 8 | Nanoparticles induce the biosynthesis and activity of the new possible therapeutic proteinase source,Talaromyces purpureogenus KJ584844显示文摘The need for the bacterial proteinase is rapidly growing,urging to catch a lowcost medium for the microbial fermentation,nanoparticles can play a vital role in this respect.The proteinase of Talaromyces purpureogenus was produced on the tubers of Helianthus tuberosus that also operated as solid support for the fermentation process.The interface amongst nitrogen sources(NH_(4)Cl and yeast extract)was investigated,applying the statistical modeling of central composite design under solid-state fermentation.The optimum medium for proteinase secretion was stimulated by 979.82 mg NH_(4)Cl and 437.68 mg yeast extract per 100 g substrate,yielding 108.15 U/g tubers.Using Plackett-Burman experimental design,the nanoparticles Co,Ni and Fe were assessed as inducers for proteinase stimulants.Co nanoparticles(5 ppm)were the greatest in both proteinase production by the fungus as well as an inducer of the proteolysis process by the enzyme when using faba bean straw as a proteinaceous substrate in the reaction mixture,liberating the extreme quantity of amino acids,compared with the lack of the nanoparticles.The findings suggest the incorporation of Co nanoparticles in both the proteinase fabrication process and during the degradation of proteinaceous materials induce proteinase catalyst.This approach could be extended to modulate the productivity and activity of similar biomolecules. | SALLY NEGM MOHAMMAD EL-METWALLY WESAM ELDIN SABER SAHAR ABO-NEIMA MAHMOUD MOUSTAFA ATTALLA EL-KOTT | 2021 | BIOCELL2021，45，1： | 0 |
| 9 | Fungal assembly of L-asparaginase using solid-state fermentation:a review显示文摘Because of its antitumor therapeutic-activity,as well as its application in food industries to improve the quality,L-asparaginase has attracted considerable attention from several investigators.In recent years,fungi have occupied advanced rank among microorganisms in the production process of the enzyme.This review is spotting the light on the advantages of fungal enzyme and its applications in the food industry and medications.The solid-state fermentation was discussed as the wide alternative and most accepted biosynthesis technique.However,some lights were also spotted to the statistical experimental design of the fermentation process,mainly on the methodology of the response surface for L-asparaginase biosynthesis by fungi.Finally,the immobilization of the enzyme and the features of the widely used solid substrates for the maximization of the production process were explored. | SALLY NASER WESAMELDIN SABER MOHAMMAD EL-METWALLY MAHMOUD MOUSTAFA ATTALLA EL-KOTT | 2020 | BIOCELL2020，44，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员